Alex Tarrabain - Apr 2, 2021 Form 4 Insider Report for CEN BIOTECH INC (CENBF)

Role
Chief Financial Officer, Director
Signature
/s/ /Alex Tarrabain
Stock symbol
CENBF
Transactions as of
Apr 2, 2021
Transactions value $
$48,000
Form type
4
Date filed
6/3/2021, 08:34 AM
Previous filing
May 28, 2021
Next filing
Jun 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CENBF Common Stock Other $0 +3K +0.17% $0.00 1.77M Jan 16, 2021 Direct F3
transaction CENBF Common Stock Other $0 +3K +0.17% $0.00 1.77M Feb 16, 2021 Direct F3
transaction CENBF Common Stock Other $0 +3K +0.17% $0.00 1.77M Mar 16, 2021 Direct F3
transaction CENBF Common Stock Award $0 +300K +20.37% $0.00 1.77M Apr 2, 2021 Direct F1
transaction CENBF Common Stock Conversion of derivative security $48K +30K +1.72% $1.60* 1.77M Apr 10, 2021 Direct F2
transaction CENBF Common Stock Other $0 +3K +0.17% $0.00 1.77M Apr 16, 2021 Direct F3
transaction CENBF Common Stock Other $0 +3K +0.17% $0.00 1.77M May 16, 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 300,000 shares of common stock of the issuer were granted by the issuer on April 2, 2021, pursuant to a restricted stock agreement pursuant to the issuer's equity compensation plan and the issuance was approved by the issuer's full board of directors.
F2 30,000 shares of common stock of the issuer were issued to the reporting person on April 10, 2021, pursuant to the conversion of a $48,000 convertible promissory note issued on October 26, 2016.
F3 3,000 shares of common stock of the issuer were issued to the reporting person on January 16, 2021, February 16, 2021, March 16, 2021, April 16, 2021 and May 16, 2021, as consideration for extending the maturity date of a promissory note dated January 14, 2018.